(Information sent by the signatory company)

SHANGHAI, March 25, 2024 /PRNewswire/ -- Filling a gap in the local HMO market, the newly launched illuma HMO Liquid Formula is the first in China to contain two essential HMOs, 2'-Fucosylactose (2'-FL) and Lacto-N-neotetraose (LNnT). This product, clinically proven, offers substantial benefits for the general well-being of newborns from 0 to 12 months. It reduces lower respiratory tract infections by 55%, bronchitis by 70% and the probability of using antibiotics by 53%.

Meanwhile, on the basis of this pioneering innovation, the national HMO clinical study project for Chinese infants has been officially launched. Nestle Research

Shiela Qiu, Wyeth Nutrition Regional Director for the Greater China Region, stated: "We are delighted to achieve another milestone in the Chinese infant nutrition market. Wyeth Nutrition's dominant position in the global milk oligosaccharides industry (HMO) is further highlighted with the introduction of China's first HMO-infused infant formula, which contains two different types of HMOs. Wyeth Nutrition is dedicated to fostering the superior growth of the Chinese infant nutrition market, bringing together global research resources and accelerating local innovation, and offering Chinese newborns more complete nutrition options in the first years of life.

Photo - https://mma.prnewswire.com/media/2370504...

View original content: https://www.prnewswire.com/news-releases/wyeth-lanza-en-china-la-primera-formula-infantil-con-dos-tipos-de-hmo-a-la-cabeza-de-la-innovacion-en-hmo-302098393.html